54
臨臨臨臨 TDM and Clinical Toxicol ogy 賴賴賴 賴賴 01-11-2008

臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Embed Size (px)

Citation preview

Page 1: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

臨床生化TDM and Clinical Toxicology

賴滄海 教授01-11-2008

Page 2: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

• Reasons for Therapeutic Drug Monitoring

• Serious consequences for Overdose• Small therapeutic index (LD50/ED50)• Poor correlation between dose and

circulation concentration and therapeutic or toxic effects

`

Page 3: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

• There is a change of patient’s physiological states that may affect circulating drug concentration

• Drug interaction may be occurring

• TDM helps in monitoring patient compliance.

Page 4: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 5: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 6: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 7: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 8: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 9: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 10: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Digoxin :

• Absorption of orally administered digoxin is variable. 25 % protein bound. Sequestered in muscle cells ( 15 - 30 times greater than plasma ) . T1/2

is 38 hours.

• Range : 0.8 to 2.0 ng/mL

Page 11: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Digoxin :

• Toxicity : Nausea, vomiting, visual disturbance, premature, ventricular contraction ( PVC ) and AV node blockage.

• Interference : Low potassium, Magnesium, Hypothyroidism potentiate digoxin action.

• Elimination : Kidney, liver .• Determined by immunoassay. DLIS cause false p

ositive result.

Page 12: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Lidocaine :• Administered IV. 70 protein bound.﹪• Range : 1.5 to 4.0μg/mL• Toxicity : CNS depression, Seizure, severe decr

ease in blood pressure and cardiac output.• Elimination : Metabolized in Liver ( first pas

s ) to MonoEthylXylidide ( MEGX ) , which is toxic but without therapeutic activity.

Page 13: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Quinidine :

• Absorption of orally administered quinidine sulfate is complete. Quinidine gluconate is a slow releasing formulation. 70 protein bound.﹪

• Range : 2 to 5 μg/mL• Toxicity : Nausea, vomiting, abdominal discom

fort, premature, ventricular contraction ( PVC ) and AV node blockage.

• Elimination : Liver

Page 14: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Procanamide :

• Absorption of orally administered drug is complete. 20 protein bound.﹪

• Range : 4 to 8 μg/mL • Toxicity : Myocardial depression and arrhythmi

a.• Elimination : Liver metabolism to N-Acetyl pro

canamide ( active metabolite ) and Kidney filtration.

Page 15: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Disopyramide :

• Absorption of orally administered drug is complete. Protein binding is highly variable.

• Range : 3 to 5 μg/mL• Toxicity : Dry mouth, constipation ( 4.5

μg/mL ) . Bradicardia, AV node blockage(> 10 μg/mL )

• Elimination : Kidney, liver.

Page 16: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Aminoglycosides : Amikacin, Gentamicin,

Kanamycin, Tobramycin.

• Administered IV or IM. Effective against gram-negative bacteria.

• Toxicity : Orotoxic, disruption of inner ear cochlear and vestibular membranes.

• Nephrotoxic, impair the function of proximal tubules of the kidney.

• Elimination : Kidney.

Antibiotics

Page 17: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Vacomycin :

• Administered IV. Protein binding is highly variable. Effective against gram-positive cocci and bacilli.

• Range : 5 to 10 μg/mL

• Toxicity : Red-man syndrome, nephrotoxicity and orotoxicity.

• Elimination : Kidney.

Page 18: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Antiepileptic drugs :

Phenobarbital, primidone• Absorption of orally administered drug is slow an

d complete. Protein binding is 50 . Long half-lif﹪e.

• Range : 15 to 40 μg/mL• Toxicity : Drowsiness, fatigue, reduced mental

capacity.• Elimination : Liver ( inducer of MFO ) and

kidney.

Page 19: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Phenytoin, Fosphenytoin

• Absorption of orally administered drug is variable and incomplete. Protein binding is 87﹪to 97 .﹪

• Range : 10 to 20 μg/mL• Toxicity : Initiation of seizure. • Hirsutism, gingival hyperplasia, vitamine D

and folate deficiency.• Elimination : Kidney ( zero order kinetic

s )

Page 20: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Valproic Acid :

• Absorption of orally administered drug is complete. Protein binding is 93 .﹪

• Range : 50 to 120 μg/mL

• Toxicity : Nausea, lethargy, weigh gain, pancreatitis, hyperammonemia and hallucinations.

• Elimination : Liver metabolism.

Page 21: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Carbamazepine :

• Absorption of orally administered drug is variable. Protein binding is 70 to 80 .﹪ ﹪

• Range : 4 to 12 μg/mL

• Toxicity : rash, leucopenia, nausea, vertigo, febrile reactions, aplastic anemia.

• Elimination : Liver ( inducer of enzyme )

Page 22: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Psychoactive drugs

Lithium• Absorption of orally administered drug is complete.• Range : 0.8 to 1.2 μg/mL• Toxicity : Apathy, lethargy, speech difficulties and

muscle weakness ( 1.2 to 2.0 mmole/L ) . Muscle rigidity, seizure and coma (> 2 mmole/L )

• Elimination : Kidney.• Analyzed with ISE, Flame emission photometry or A

AS.

Page 23: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Tricyclic antidepressants

Impiramine, amitriptyline and active

metabolites, doxepin.• Absorption of orally administered drug is variabl

e. Protein binding is 85 to 95 .﹪ ﹪• Toxicity : Drowsiness, constipation, blurred vis

ion, memory loss ( 2X upper limit ) . Seizure, cardiac arrhythmia and unconsciousness.

• Elimination : Liver.

Page 24: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Bronchodilators

Theophylline• Absorption of orally administered drug is v

ariable. Protein binding is 50 .﹪• Range : 10 to 20 μg/mL• Toxicity : Nausea, vomiting and diarrhea.

Cardiac arrhythmia, seizure (> 30 μg/mL )

• Elimination : Kidney and liver.

Page 25: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Immunosuppressive drugs

Cyclosporine• Absorption of orally administered drug is variabl

e ( 5 to 50﹪ ﹪) . Sequestered in cells.• Range : 100-300 ng/mL• Toxicity : Renal tubular and glomerular dysfun

ction, hypertension.• Elimination : Liver.• Determined with immunoassays. Whole blood is

the specimen of choice.

Page 26: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 27: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

The categories with the largest number of deaths are as follows:

Page 28: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 29: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 30: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 31: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 32: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Salicylate• Aspirin (Acetylsalicylic acid) has analgesic, antipyretic and antiinflammatory

properties.

Therapeutic concentration: analgesic-antipyretic (lower than 60 mg/L) anti-inflammatory (150 to 300 mg/L)

Aspirin interferes with platelet aggregation and thus prolongs bleeding times.

Page 33: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Pharmacologic effect of salicylates

• Stimulate central respiratory center

• Uncoupling of oxidative phosphorylation

• Enhance anaerobic glycolysis, Inhibite Kreb’s cycle and transaminase enzyme.

• Respiratory alkalosis predominates in children over age 4 and in adults.

Page 34: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

• Respiratory alkalosis (19 % )

• Metabolic acidosis (15 % )

• Combined (61 % )

motality was associated with acidemia

Page 35: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Fig.25-13. Nomogram for estimating the severity of acute salicylate intoxication.(From Done, A.K.:salicylate intoxication: Significance of measurements of salicylate in blood in cases of acute ingestion. Pediatrics, 26:800, 1960. Reproduced by permission of Pediatrics.)

Page 36: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Symptoms of salicylate intoxication

• Tinnitus (耳鳴)• Diaphoresis (出汗)• Hyperthermia• Hyperventilation• Nausea, vomiting• Acid-base disturbances• CNS effects lethargy, disorientation, coma and seizures.

Page 37: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Treatment

• Ipecac to induce vomiting

• Correction of acid-base and electrolyte imbalance, activated charcoal to prevent absorption

• Hemodialysis

Page 38: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Screening Assay for Acetaminophen and Salicylate

• Acetaminophen After acid hydrolysis, the sample was reacted with

o-cresol in basic solution to show blue color.

• Salicylate Salicylates reacted with Ferric chloride solution to

produce a violet color reaction.

(Interferant: Diflunisal, labetalol, keto acids)

Page 39: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Methemoglobin

• Less than 1.5 % of total hemoglobin in normal blood

• Caused by methhemoglobin reductase deficiency or ingestion of nitrites, nitrates, phenacetin, phenazopyridine, sulfonamides, sulfones, aniline dyes.

• Determined spectrophotometrically at

630 nm

Page 40: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Alcohols

• Ethanol

• Methanol

• Ethyleneglycol

• Isopropylalcohol

Page 41: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 42: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Effects of Ethanol

• Cardiovascular system—Increase high-density lipoprotein

• Central nervous system-CNS depression (Respiratory center, coma, death)

• Gastrointestinal tract-Stimulate the production of gastric juices

• Kidney-Diuretics ( Inhibit the secretion of ADH)• Liver-Fatty liver,Cirrhosis • Fetal alcohol syndrome

Page 43: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Determination of Ethanols

1. Enzymatic

2. Headspace-GC

3. Breath-testing device (amount of ethanol in 1mL of blood equals to 2100mL of breath air)

Henry’s law

Page 44: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 45: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 46: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Ethyleneglycol

資料來源: 2007 年 5月 7日自由時報

Page 47: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 48: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008
Page 49: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Carbon Monoxide

Page 50: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

• Lithium Use to treat manic-depressive illness. It enhances reuptake of neurotransmitters, thus

produces sedating effect on the CNS

• Toxicity apathy, sluggishness, drowsiness, lethargy, speech

difficulties, irregular tremors, muscle weakness, ataxia, epileptic seizures.

Determined with ISE or Atomic Absorption

Spectrometry, Flame emission photometry

Page 51: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Lead• Toxicity Inhibits amino levulinic acid dehydratase (causes accu

mulation of protoporphyrin in RBC)

Forms covalent bonds with the-SH group of cysteine in proteins (Nerve cells are particular susceptible)

• Determination whole blood was analyzed with atomic absorption spe

ctrometry

Page 52: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

•Fig.25-27. Effects of inorganic lead on children and adults (lowest observable adverse effect levels). (From Royce, S.E., Needleman, H. L., Eds.: Case Studies in Environmental Medicine: Lead Toxicity. U.S. Public Health Service, ATSDR, 1990.)

Page 53: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

Iron

• Toxicity Severe irritation of the epithelial lining of the GI tract a

nd results in hemosiderosis, which may develop into hepatic cirrhosis.

• Hemosiderosis A term used to imply iron overload without associated t

issue injury Determined spectrophotometrically after reaction with

Bathophenanthroline or Ferrozine

Page 54: 臨床生化 TDM and Clinical Toxicology 賴滄海 教授 01-11-2008